PCR remains one of the most widely used technologies in molecular biology and clinical diagnostics, and its success relies heavily on the performance of DNA polymerases.
DNA polymerases catalyze the synthesis of new DNA strands using an existing DNA template and dNTPs as substrates. The discovery of DNA Polymerase I in Escherichia coli in 1957 marked a milestone in understanding DNA replication. Later, the isolation of thermostable Taq DNA Polymerase from Thermus aquaticus revolutionized PCR by enabling repeated thermal cycling without enzyme replenishment.
Taq DNA Polymerase consists of 832 amino acids with a molecular weight of approximately 94 kDa. Its structure can be divided into three major domains:
- 5′→3′ Exonuclease Domain (aa 1–291): Responsible for probe hydrolysis and widely utilized in TaqMan assays.
- 3′→5′ Exonuclease-Like Domain (aa 292–423): Structurally present but lacks proofreading activity.
- 5′→3′ Polymerase Domain (aa 424–832): The catalytic core responsible for DNA synthesis.
The polymerase domain adopts the classical "right-hand" architecture:
- Thumb domain: Maintains interaction with the primer-template complex and enhances processivity.
- Finger domain: Facilitates dNTP binding.
- Palm domain: Contains the catalytic center where divalent metal ions coordinate nucleotide incorporation.
Figure 1. Three-dimensional structure of Taq DNA Polymerase.
The Challenge of Direct PCR in Molecular POCT
Direct PCR technologies are increasingly adopted in molecular point-of-care testing (POCT) because they eliminate nucleic acid extraction, significantly reducing workflow complexity and turnaround time.
However, clinical samples often contain substances that interfere with PCR performance. These inhibitors can negatively impact enzyme activity, resulting in reduced amplification efficiency, decreased sensitivity, or even complete reaction failure.
Developing a DNA polymerase capable of maintaining robust performance in the presence of inhibitors is therefore essential for next-generation molecular diagnostic workflows.
Engineering a More Robust Taq Polymerase
Leveraging Yeasen's proprietary ZymeEditor™ Enzyme Engineering Platform, researchers systematically optimized Taq DNA Polymerase through: Structure-guided mutagenesis, Multi-source sequence comparison, Site-directed mutagenesis, Random mutagenesis and directed evolution, Fragment recombination, High-pressure functional screening.
Candidate variants were evaluated using Yeasen's MTPS high-throughput screening platform, assessing multiple parameters including:
- Thermal stability
- DNA-binding affinity
- Polymerase activity
- Exonuclease activity
- Inhibitor tolerance
By simulating real-world direct amplification scenarios such as swab-based testing, the team identified critical factors affecting enzyme performance and optimized screening conditions accordingly.
This effort ultimately led to the development of: Hieff UNICON™ Robust HotStart Taq DNA Polymerase (Cat#14325)
An engineered HotStart Taq polymerase specifically designed to maintain strong amplification performance in the presence of challenging PCR inhibitors.
1. Exonuclease Activity
Seven engineered Taq variants were assessed for exonuclease activity following different sample pretreatment procedures.
Results demonstrated that:
- Standard ultrasonic treatment (2 minutes) did not significantly affect exonuclease activity.
- Swab materials themselves showed minimal impact on enzyme performance.
- Vigorous vortexing that generated visible flocculent material reduced exonuclease activity.
|
Condition |
Mutant 1 |
Mutant 2 |
Mutant 3 |
Mutant 4 |
Mutant 5 |
|
Water |
320.2 |
210.6 |
569.4 |
609.2 |
470.1 |
|
Water + Swab |
360.6 |
259.1 |
473.7 |
595.2 |
460.3 |
|
Condition |
Mutant 5 |
Mutant 6 |
|
Water |
143.6 |
246.7 |
|
Water + Swab |
169.8 |
253.9 |
|
Water + Swab (Flocs) |
98.1 |
138.1 |
Figure 2. Exonuclease activity of engineered Taq variants under different sample processing conditions.
2. Polymerase Activity Assessment
Long-range PCR was performed to evaluate the impact of various sample components on polymerase activity.
Test conditions included: Water control, Collection swabs, Direct PCR lysis buffer
Results showed:
- Swab materials alone had little effect on polymerase performance.
- Direct PCR lysis buffer significantly inhibited polymerase activity.
Figure 3. Long-range PCR amplification results under different sample treatment conditions.
3. Direct Amplification from Swab Samples
Throat swab samples were collected and processed using direct PCR lysis buffer with agitation. Equivalent template concentrations were prepared using either lysis buffer or TE buffer.
qPCR assays formulated with Cat#14325 were compared against commercially available competitor products.
Results demonstrated that the Cat#14325 system exhibited superior inhibitor tolerance and supported reliable direct amplification from swab samples.
Figure 4. Comparison of direct swab amplification performance between Cat#14325 and commercially available alternatives.
4. Direct Amplification from Plasma Samples
Clinical plasma samples were diluted using either plasma matrix or TE buffer to generate equivalent template concentrations. qPCR reactions formulated with Cat#14325 were compared with competing products.
Results showed that: Cat#14325 maintained robust amplification performance in plasma-containing reactions.
The system tolerated plasma concentrations of up to approximately 30% of the final reaction volume.
Figure 5. Comparison of direct plasma amplification performance between Cat#14325 and commercially available alternatives.
Related Products
|
Product Type |
Cat. No. |
Product Name |
Key Features |
|
HotStart Taq Polymerase |
14325ES |
Exceptional tolerance to sputum, stool, blood, swabs, and other inhibitory samples |
|
|
14321ES |
Hieff UNICON UCF.ME™ Advanced HotStart Taq DNA Polymerase (20 U/μL) |
Ultra-low host residuals and enhanced stability |
|
|
14319ES |
Hieff UNICON UCF.ME™ Advanced HotStart E-Taq DNA Polymerase (20 U/μL) |
High sensitivity and specificity with low residual contamination |
|
|
10726ES |
Reliable detection of low-copy targets with strong fluorescence signals |
||
|
10717ES |
Strong tolerance to blood and swab-derived inhibitors |
||
|
10723ES |
Hieff Unicon™ HotStart J-Taq DNA Polymerase (5 U/μL) |
Improved amplification uniformity in multiplex PCR |
|
|
10729ES |
Robust amplification efficiency and broad compatibility |
||
|
14317ES |
Hieff UNICON™ HotStart High Tolerant Taq DNA Polymerase (5 U/μL) |
Resistant to uracil and bisulfite treatment; ideal for methylation PCR |
|
|
14318ES |
Hieff UNICON™ HotStart Super Specific Taq DNA Polymerase (5 U/μL) |
Enhanced discrimination of 3′ mismatches for ARMS and SNP genotyping |
|
|
qPCR Mix |
16924ES |
Ultra-fast, low-residual, fully premixed formulation |
|
|
RT-qPCR Mix |
16930ES |
Hifair™ Universal Advanced Multiplex One Step RT-qPCR Mix (UDG Plus) |
Fast, High Sensitivity, Inhibition-Tolerant |
|
16921ES |
High Concentration, All-in-One (5X) |
||
|
16913ES |
Hifair™ Superpro Fast One Step RT-qPCR Master Mix (UDG Plus) |
Fully Premixed, Fast |